Trials / Completed
CompletedNCT03007875
High-activity Natural Killer Immunotherapy for Small Metastases of Non-small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Fuda Cancer Hospital, Guangzhou · Academic / Other
- Sex
- All
- Age
- 30 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is the safety and efficacy of high-activity natural killer immunotherapy to small metastases of non-small cell lung cancer.
Detailed description
By enrolling patients with small metastases of non-small cell lung cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of high-activity natural killer cells. The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | high-activity natural killer | Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v. |
Timeline
- Start date
- 2016-12-01
- Primary completion
- 2017-12-01
- Completion
- 2019-09-01
- First posted
- 2017-01-02
- Last updated
- 2019-09-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03007875. Inclusion in this directory is not an endorsement.